Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments

Fineline Cube Jul 13, 2026
Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

TransThera Secures NMPA Approval for Phase 2 Trial of TT-00973 in Combination with Firmonertinib for EGFR-Mutant NSCLC

Fineline Cube Jul 13, 2026
Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Fineline Cube Jul 10, 2026
Company Drug

Huadong Medicine’s HDM3001, a Biosimilar to Stelara, Accepted for Review by NMPA

Fineline Cube Aug 14, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Company Deals

Cascade Pharmaceuticals Secures RMB140 Million in Financing to Advance FXR Agonist Clinical Trials

Fineline Cube Aug 14, 2023

Shanghai-based sino-foreign joint venture, Cascade Pharmaceuticals, Inc., has reportedly raised RMB140 million in a recent...

Company Deals

Migrasome Therapeutics Secures Over RMB100 Million in Angel+ Funding Round

Fineline Cube Aug 14, 2023

Beijing-based biotech startup Migrasome Therapeutics has reported raising upwards of RMB100 million in its angel...

Company Drug

CanSino BiologicsLaunches Phase III Trial for DTcP Vaccine in Infants and Young Children

Fineline Cube Aug 14, 2023

CanSino Biologics Inc. a leading China-based vaccines specialist (HKG: 6185), has announced the initiation of...

Policy / Regulatory

Hunan HSA Implements Direct BMI Fund Payments for VBP-Winning Drugs and Consumables

Fineline Cube Aug 11, 2023

The Hunan Healthcare Security Administration (HSA) bureau has released a notice stating that effective from...

Policy / Regulatory

SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China

Fineline Cube Aug 11, 2023

The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...

Company Drug

Cutia Therapeutics’ CU-10201 Enters Priority Review for Acne Treatment in China

Fineline Cube Aug 11, 2023

Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its CU-10201, a 4% minocycline...

Company Deals

Huadong Medicine Secures Exclusive Rights to Arcutis’ Daxas in Greater China and South-East Asia

Fineline Cube Aug 11, 2023

Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant licensing agreement with Arcutis (NASDAQ:...

Company Deals

Medtronic Partners with APMG to Advance Orthopedic Treatment Services in China

Fineline Cube Aug 11, 2023

US-based Medtronic Inc., (NYSE: MDT) has entered into a partnership with China’s private healthcare group...

Company Deals

Everest Medicines and Shanghai Pharmaceuticals Deepen Partnership for Drug Distribution in China

Fineline Cube Aug 11, 2023

China-based Everest Medicines (HKG: 1952) has announced a strategic partnership with Shanghai Pharmaceuticals marking a...

Company Drug

NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma

Fineline Cube Aug 11, 2023

The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...

Company Medical Device

Beijing Balance Medical Receives Approval for Innovative Expandable Artificial Heart Valve in China

Fineline Cube Aug 11, 2023

Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology company in China,...

Company Deals

WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership

Fineline Cube Aug 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Company Deals

Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China

Fineline Cube Aug 11, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...

Company

Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales

Fineline Cube Aug 11, 2023

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...

Company Legal / IP

Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China

Fineline Cube Aug 11, 2023

A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit...

Company

Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars

Fineline Cube Aug 10, 2023

US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US...

Company

Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...

Company Deals

Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy

Fineline Cube Aug 10, 2023

US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...

Posts pagination

1 … 517 518 519 … 693

Recent updates

  • InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments
  • TransThera Secures NMPA Approval for Phase 2 Trial of TT-00973 in Combination with Firmonertinib for EGFR-Mutant NSCLC
  • PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates
  • Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia
  • Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments

Company Drug

TransThera Secures NMPA Approval for Phase 2 Trial of TT-00973 in Combination with Firmonertinib for EGFR-Mutant NSCLC

Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Company Drug

Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.